Vivozon Registers Chinese Patent for Oral Non-Narcotic Analgesic VVZ-2471

Vivozon, a company specializing in innovative drug development, announced on the 23rd that it has completed the registration of a substance patent in China for the oral non-narcotic analgesic VVZ-2471 and its derivatives, which are being developed as treatments for pain and addiction.

The patent registration in China is the third, following the United States and South Africa. Examination procedures are underway in other major countries as well. This patent secures exclusive rights within China based on the superior analgesic effects and distinctiveness of VVZ-2471 compared to existing compounds, and it also covers related compounds.

VVZ-2471 is an oral drug candidate discovered through Vivozon’s proprietary multi-target drug development technology. It has demonstrated not only analgesic efficacy but also effectiveness in treating narcotic addiction. The company is conducting clinical studies to develop it as a treatment for neuropathic pain domestically and as a treatment for narcotic addiction in the United States.

Notably, Vivozon received approval for a Phase 2 clinical trial application (IND) for VVZ-2471 targeting patients with postherpetic neuralgia in South Korea last June. Alongside the oral analgesic VVZ-2471, the company plans to widely utilize Anapraju, Korea’s 38th new drug approved by the Ministry of Food and Drug Safety last year, for pain treatment.

A Vivozon representative stated, “We expect the results of the domestic Phase 2 clinical trial of VVZ-2471 to be available within this year,” adding, “The registration of the patent in China confirms the analgesic efficacy of VVZ-2471 in a painkiller market lacking non-narcotic analgesics with efficacy comparable to narcotic analgesics.”

They continued, “Our goal is to develop VVZ-2471 as a non-narcotic oral analgesic for acute and chronic pain and to lead the global analgesic market together with Anapraju.”

Furthermore, in the United States, where addiction and abuse of narcotic analgesics (opioids) such as fentanyl have become serious social issues, Vivozon is preparing for a Phase 2 clinical trial to develop VVZ-2471 as a treatment for narcotic and drug addiction. To this end, Vivozon has applied for research funding from the National Institute on Drug Abuse (NIDA), part of the U.S. National Institutes of Health (NIH), and is collaborating with local drug addiction treatment experts.

This content was produced with the assistance of AI translation services.